Willow vs Oak Longevity: Support vs Low Price Comparison

Willow vs Oak Longevity compares two telehealth GLP-1 programs: Willow emphasizes oral GLP-1 with structured progress tracking and follow-up, starting price 299, while Oak Longevity emphasizes low-cost compounded GLP-1 options, with semaglutide from $133/month and tirzepatide from $199/month. Quick verdict: choose Oak for lower per-month pricing and no subscription, choose Willow if you want a structured digital follow-up model.

Explore Willow’s progress tracking program

How they differ at a glance: Willow vs Oak Longevity

This comparison focuses on five distinctive differences supported by the source: pricing structure, follow-up and tracking, medication type and regulatory notes, clinical review workflow, and best-fit patients.

Comparison table: key criteria

Pricing structure and value

Oak Longevity advertises semaglutide from $133/month and tirzepatide from $199/month with a one-price-for-all-dosages approach, no subscriptions, and free shipping and health coaching included. Willow lists a starting price of 299 and positions its offering as a structured program rather than a medication subscription. The evidence shows Oak is oriented toward lower per-month costs while Willow emphasizes program design.

View Oak Longevity pricing and plans

Support model and follow-up

Willow promotes progress tracking tools and follow-up consultations as part of a telehealth-first weight management journey, aimed at converting GLP-1 efficacy into sustainable outcomes. Oak Longevity includes free health coaching with every plan and free shipping, but highlights a no-subscription, one-price model. Both emphasize clinician oversight; Willow highlights structured behavioral support while Oak highlights included coaching and streamlined purchase.

Medication type, regulatory notes, and clinical workflow

Both sources include the regulatory caution that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Oak explicitly lists compounded semaglutide and tirzepatide and notes no video call is required, with licensed physicians reviewing cases asynchronously. Willow states treatment is available only when a licensed clinician determines it is medically appropriate and frames the program as telehealth-first with follow-up support.

Who is each service best for

According to the captured evidence, Willow is best for users who want structured digital follow-up and behavioral scaffolding alongside oral GLP-1 treatment. Oak Longevity is best for cost-conscious patients with an uncomplicated health history who want affordable compounded GLP-1 online, with no video call or insurance, and who accept compounded medications and the stated billing practices.

Start Willow’s structured weight management path

Practical differences to weigh

Decide based on priorities shown in the sources: if lowest monthly price and no subscription are the priority, Oak Longevity lists semaglutide from $133/month and tirzepatide from $199/month and emphasizes one flat price and no membership fees. If structured follow-up, progress tracking tools, and a program orientation matter more, Willow highlights licensed telehealth team support and follow-up consultations at a starting price of 299.

Choose Willow vs Oak Longevity

Choose Willow if you want a telehealth-first oral GLP-1 program that emphasizes progress tracking tools and follow-up consultations and are comfortable with a starting price of 299.

Choose Willow for structured follow-up

Choose Oak Longevity if your priority is lower advertised monthly pricing and a one-price, no-subscription model with free health coaching and free shipping; Oak lists semaglutide from $133/month and tirzepatide from $199/month and uses asynchronous clinical review.

Choose Oak Longevity for low-cost options

Willow vs Oak Longevity: weigh structured follow-up and program orientation against lower per-month pricing and a no-subscription model when making your choice.